Although we failed to observe a correlation between FGF-2 expression and tumor location, KIT mutational status, gender and low/high-risk groups of treatment-naive GISTs (p > 0.05; Fisher’s exact probability test) or age (p > 0.05; ANOVA) and survival (p > 0.05; Kaplan–Meier’s test), we found the significant correlation between FGF-2 expression in GIST specimens and IM treatment (p = 0.01275; Fisher’s exact probability test). This evidence concerns the gene FGF2 and gastrointestinal stromal tumor.